enGene Holdings Inc. (ENGN)
Automate Your Wheel Strategy on ENGN
With Tiblio's Option Bot, you can configure your own wheel strategy including ENGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENGN
- Rev/Share 0.0094
- Book/Share 3.9272
- PB 2.0498
- Debt/Equity 0.0412
- CurrentRatio 10.3382
- ROIC 0.0553
- MktCap 412093757.0
- FreeCF/Share -1.8617
- PFCF -4.3319
- PE -9.5458
- Debt/Assets 0.0336
- DivYield 0
- ROE -0.1813
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ENGN | Piper Sandler | -- | Overweight | -- | $26 | Feb. 18, 2025 |
| Downgrade | ENGN | UBS | Buy | Neutral | $34 | $7 | Feb. 14, 2025 |
| Initiation | ENGN | H.C. Wainwright | -- | Buy | -- | $25 | Dec. 23, 2024 |
| Initiation | ENGN | Oppenheimer | -- | Outperform | -- | $30 | Aug. 28, 2024 |
News
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regulatory submissions, and medical affairs. He mos.
Read More
enGene to Participate in Upcoming Investor Conferences
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral gene therapy company, today announced that management will participate in the following investor conferences in September: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Time: 8:45 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference Date: Monday, September 8, 2025 Time: 1:30 p.m. ET Morgan Stanley 23rd Annual Global Healthcare Conference Date:.
Read More
enGene to Participate in Upcoming Investor Conferences
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,.
Read More
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.
Read More
About enGene Holdings Inc. (ENGN)
- IPO Date 2022-02-01
- Website https://www.engene.com
- Industry Biotechnology
- CEO Ronald H. W. Cooper
- Employees 56